Gene Kim, MD
Advanced Heart Failure and Transplant Cardiology · Chicago, ILNPI 1598923005
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,003 of the $8,504 with a category attached, or 82.4%. 29 manufacturers reported payments, led by Abbott at 47.9% of the total. Reporting peaked in 2019 at $2,042 and has fallen 64.7% since, to $721 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in IL, where the typical reported total is $11,038.
Across 202 payments — averaging $42.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Ancora Heart, Inc.$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$700
- Cvrx, Inc.$591
- Medtronic$539
- Pfizer$235
- plus $1K from 23 others
Across 139 payments — averaging $830.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$73K
- Boehringer Ingelheim Pharma GmbH & Co.kg$23K
- Abbott$15K
- E.r. Squibb & Sons, L.L.C.$5K
What the payments were for
- Travel & lodging$1,50018%
- Food & beverage$7,00382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 75 | $4,075 |
| Ancora Heart, Inc. | 4 | $1,238 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 35 | $700 |
| Cvrx, Inc. | 16 | $591 |
| Medtronic(2 entities) | 8 | $539 |
| Pfizer | 14 | $235 |
| Paragonix Technologies, Inc. | 2 | $138 |
| E.r. Squibb & Sons, L.L.C. | 7 | $129 |
| Novartis | 5 | $97 |
| AstraZeneca | 5 | $87 |
| Amgen | 4 | $87 |
| Merck | 4 | $70 |
| Portola Pharmaceuticals, LLC | 3 | $64 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Bridgebio Pharma, Inc. | 1 | $45 |
| Scpharmaceuticals Inc. | 2 | $44 |
| Boehringer Ingelheim | 2 | $36 |
| ZOLL Circulation Inc | 1 | $35 |
| United Therapeutics Corporation | 2 | $30 |
| Impulse Dynamics (USA) Inc. | 1 | $28 |
| Procyrion, Inc. | 1 | $27 |
| Phathom Pharmaceuticals, Inc. | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Akcea Therapeutics, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,504 in reported general payments places this provider in the 40th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 87 | $1,108,709 |
| AdempasRiociguat | 39 | $555,323 |
| CamzyosMavacamten | 21 | $158,307 |
| Ambrisentan | 16 | $65,586 |
| EntrestoSacubitril/Valsartan | 44 | $41,702 |
| Tadalafil | 22 | $32,852 |
| EliquisApixaban | 16 | $15,524 |
| Metoprolol Succinate | 46 | $691 |
| Torsemide | 33 | $599 |
| Valsartan | 20 | $489 |
| Spironolactone | 42 | $337 |
| Furosemide | 36 | $224 |
| Potassium Chloride | 17 | $221 |
| Pantoprazole Sodium | 17 | $209 |
| Rosuvastatin Calcium | 17 | $208 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $129 | $158,30721 claims |
| NovartisEntresto | $97 | $41,70244 claims |
| PfizerEliquis | $235 | $15,52416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Chicago
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Jane WilcoxChicago$220K
- Manreet KanwarChicago$162K
- Jonathan GrinsteinChicago$128K
- Bow ChungChicago$86K
- Quentin YoumansChicago$75K
- Anjan TibrewalaChicago$58K
- Faraz AhmadChicago$36K
- Ike OkwuosaChicago$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.